Peer-reviewed veterinary case report
Effect of new drug TT001 on acid reflux in dogs under anesthesia
By Glovéus, A et al.·Published in The Journal of small animal practice·2026·msholm Referral Small Animal Hospital·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of novel metabotropic glutamate receptor 5 antagonist on gastroesophageal reflux in dogs during anaesthesia.
- Species:
- dog
Plain-English summary
A group of 119 dogs undergoing anesthesia were monitored for gastroesophageal reflux, which can lead to serious complications like aspiration pneumonia. They received either a new drug called TT001 or a placebo shortly before anesthesia. The results showed that about 45% of the dogs experienced reflux, with no significant difference between those given the active drug and those given the placebo. This suggests that TT001 does not effectively reduce the risk of reflux during anesthesia in dogs.
People also search for: dog reflux during anesthesia · TT001 for dogs · gastroesophageal reflux in dogs · dog anesthesia risks
Abstract
OBJECTIVES: Gastroesophageal reflux during anaesthesia is a common event occurring in dogs with the potential to cause oesophageal injury and aspiration pneumonia. The objective of the current study was to evaluate the effect of the novel metabotropic glutamate receptor 5 antagonist TT001 on gastroesophageal reflux during anaesthesia in dogs using two different protocols. MATERIALS AND METHODS: One hundred and nineteen client-owned dogs were included and randomly assigned to receive test-drug containing either active TT001 (n = 58) or placebo vehicle (n = 61). In protocol 1 (n = 77), test-drug was administered shortly before induction and in protocol 2 (n = 42) test-drug was administered 15 minutes before standardised pre-anaesthetic drugs. Gastroesophageal reflux (pH <4) was measured and recorded using oesophageal pH-metry throughout the duration of the anaesthesia. RESULTS: Gastroesophageal reflux was registered in 45.4% of dogs, in protocol 1: 44.2%, and in protocol 2: 47.6%. No overall statistically significant difference between the dogs receiving active TT001 (group A, 48.3%) and placebo (group B, 42.6%) was observed, regardless of the protocol tested (protocol 1: group A: 47.4%, group B: 41.0%; protocol 2: group A: 50.0%, group B: 45.5%). CLINICAL SIGNIFICANCE: Administration of metabotropic glutamate receptor 5 antagonist TT001 as a single intravenous bolus injection before or after pre-anaesthetic drugs has limited effect on the incidence of gastroesophageal reflux in anaesthetised dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41251221/